Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab AS's book value per share for the quarter that ended in Mar. 2026 was kr598.39.
During the past 12 months, Genmab AS's average Book Value Per Share Growth Rate was 3.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.50% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 27.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Genmab AS was 97.10% per year. The lowest was -40.50% per year. And the median was 18.40% per year.
Genmab AS's current price is kr1847.50. Its book value per share for the quarter that ended in Mar. 2026 was kr598.39. Hence, today's PB Ratio of Genmab AS is 3.09.
During the past 13 years, the highest P/B Ratio of Genmab AS was 19.72. The lowest was 2.12. And the median was 7.45.
Genmab AS (CHIX:GMABc) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Genmab AS Book Value per Share Related Terms
Genmab AS Book Value per Share Historical Data
* Premium members only.
The historical data trend for Genmab AS's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:GMABC vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Genmab AS's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's PB Ratio distribution charts can be found below:
* The bar in red indicates where Genmab AS's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of kr598.39 mean?
Genmab AS (CHIX:GMABC) has a Book Value per Share of kr598.39 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Genmab AS and its competitors.
Is Genmab AS's Book Value per Share too high?
Genmab AS's current Book Value per Share is kr598.39. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Book Value per Share compare to VRTX and REGN?
Genmab AS's Book Value per Share of kr598.39 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Genmab AS and its competitors. Genmab AS's current Book Value per Share is kr598.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (CHIX:GMABC) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2,309.15, compared to a current price of kr1,847.50 — trading 20% below its estimated fair value. The current Book Value per Share is kr598.39. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Genmab AS (CHIX:GMABC), the current Book Value per Share is kr598.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (CHIX:GMABC) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of kr1,847.50 is trading 20% below its estimated GF Value™ of kr2,309.15.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for CHIX:GMABC:
Book Value per Share: kr598.39
GF Value™: kr2,309.15 vs. price of kr1,847.50 (20% below fair value)
No single metric tells the full story. See the CHIX:GMABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score
Get the complete analysis for CHIX:GMABC
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:GMABC has been successfully added to your 
